EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A New Era in the Management of Patients with Diabetic Kidney Disease using Four Pillars of Therapy

Christodoula Kourtidou, Panagiotis I. Georgianos, Vassilios Liakopoulos, Christos Savvopoulos, Konstantinos Tziomalos

Journal of Atherosclerosis Prevention and Treatment · 2026-01 · 17 (1) · 13-19

DOI: 10.4103/aptj.aptj_27_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Atherosclerosis Prevention and Treatment, online erschienen am 13.07.2026. Verfasst von Christodoula Kourtidou und 4 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is the most common comorbidity in patients with type 2 diabetes (T2D), and its presence substantially magnifies the risk for adverse cardiorenal outcomes. For nearly 20 years, the pharmacological blockade of the renin–angiotensin system (RAS) was the only pillar of therapy to offer cardiorenal protection in these patients. Over the last 6 years, newer therapies have been added to our therapeutic armamentarium, offering promise for more effective management of the substantial residual cardiorenal risk of these patients. Large Phase 3 clinical trials have demonstrated additive cardiorenal protective benefits of sodium–glucose cotransporter type 2 (SGLT-2) inhibitors, nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone, and glucagon-like peptide-1 receptor agonist semaglutide relative to placebo in patients with albuminuric CKD and T2D who are receiving standard-of-care treatment with a RAS-blocker. Evidence from the recently completed CONFIDENCE trial suggests that the cardiorenal protective effects are greater in magnitude and overadditive when SGLT-2 inhibitors are used in combination with finerenone. In this study, we build the puzzle of four pillars of therapy for the improvement of cardiorenal outcomes in patients with CKD associated with T2D. We provide evidence from recent randomized trials, and we discuss the concept of combined treatment for maximal efficacy and better tolerability with fewer adverse events.

Zitieren

APA

Kourtidou, C., Georgianos, P. I., Liakopoulos, V., Savvopoulos, C., & Tziomalos, K. (2026). A New Era in the Management of Patients with Diabetic Kidney Disease using Four Pillars of Therapy. Journal of Atherosclerosis Prevention and Treatment, 17(1), 13-19. https://doi.org/10.4103/aptj.aptj_27_26

Vancouver

Kourtidou C, Georgianos PI, Liakopoulos V, Savvopoulos C, Tziomalos K. A New Era in the Management of Patients with Diabetic Kidney Disease using Four Pillars of Therapy. Journal of Atherosclerosis Prevention and Treatment. 2026;17(1):13-19. doi:10.4103/aptj.aptj_27_26

BibTeX
@article{Kourtidou2026,
  author = {Kourtidou, Christodoula and Georgianos, Panagiotis I. and Liakopoulos, Vassilios and Savvopoulos, Christos and Tziomalos, Konstantinos},
  title = {A New Era in the Management of Patients with Diabetic Kidney Disease using Four Pillars of Therapy},
  journal = {Journal of Atherosclerosis Prevention and Treatment},
  year = {2026},
  volume = {17},
  number = {1},
  pages = {13--19},
  doi = {10.4103/aptj.aptj_27_26}
}
Kostenlos starten →